TCR2 Therapeutics Stock Forecast, Price & News

TCR2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

Is TCR2 Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics or view top-rated stocks.

How has TCR2 Therapeutics' stock been impacted by Coronavirus?

TCR2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TCRR shares have decreased by 58.5% and is now trading at $3.56.
View which stocks have been most impacted by COVID-19.

Are investors shorting TCR2 Therapeutics?

TCR2 Therapeutics saw a decline in short interest in December. As of December 31st, there was short interest totaling 1,130,000 shares, a decline of 43.5% from the December 15th total of 2,000,000 shares. Based on an average daily volume of 820,900 shares, the days-to-cover ratio is currently 1.4 days. Approximately 3.9% of the shares of the stock are sold short.
View TCR2 Therapeutics' Short Interest.

When is TCR2 Therapeutics' next earnings date?

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for TCR2 Therapeutics.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.69) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.06.
View TCR2 Therapeutics' earnings history.

What price target have analysts set for TCRR?

9 analysts have issued 1-year price targets for TCR2 Therapeutics' stock. Their forecasts range from $5.00 to $55.00. On average, they anticipate TCR2 Therapeutics' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 546.1% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics or view top-rated stocks among Wall Street analysts.

Who are TCR2 Therapeutics' key executives?

TCR2 Therapeutics' management team includes the following people:

• Garry E. Menzel, President, Chief Executive Officer & Director
• Robert Hofmeister, Chief Scientific Officer
• Alfonso Quintás-Cardama, Chief Medical Officer
• Peter Olagunju, Chief Technical Officer
• Gregg McConnell, Head-Business Development

Who are some of TCR2 Therapeutics' key competitors?

Some companies that are related to TCR2 Therapeutics include bluebird bio (BLUE), Mesoblast (MESO), AlloVir (ALVR), Graphite Bio (GRPH), Aura Biosciences (AURA), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Omega Therapeutics (OMGA), Tarsus Pharmaceuticals (TARS), Athira Pharma (ATHA), Finch Therapeutics Group (FNCH), Tenaya Therapeutics (TNYA), Talaris Therapeutics (TALS), Ikena Oncology (IKNA) and BioAtla (BCAB).
View all of TCRR's competitors.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Marquette Asset Management LLC (0.05%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends for TCR2 Therapeutics.

Which major investors are buying TCR2 Therapeutics stock?

TCRR stock was purchased by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC.
View insider buying and selling activity for TCR2 Therapeutics or or view top insider-buying stocks.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $3.56.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics has a market capitalization of $136.06 million. The company earns $-67.12 million in net income (profit) each year or ($2.46) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

TCR2 Therapeutics employs 118 workers across the globe.

What is TCR2 Therapeutics' official website?

The official website for TCR2 Therapeutics is www.tcr2.com.

Where are TCR2 Therapeutics' headquarters?

TCR2 Therapeutics is headquartered at 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at (617) 949-5200 or via email at [email protected].